Literature DB >> 18991116

Sample size re-estimation for adaptive sequential design in clinical trials.

Ping Gao1, James H Ware, Cyrus Mehta.   

Abstract

There is considerable interest in methods that use accumulated data to modify trial sample size. However, sample size re-estimation in group sequential designs has been controversial. We describe a method for sample size re-estimation at the penultimate stage of a group sequential design that achieves specified power against an alternative hypothesis corresponding to the current point estimate of the treatment effect.

Mesh：

Year:  2008        PMID： 18991116     DOI： 10.1080/10543400802369053

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN： 1054-3406            Impact factor:   1.051


  9 in total

Review 1.  Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.

Authors:  W Charles Huskins; Vance G Fowler; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

2.  Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.

Authors:  Vincent C Marconi; Athimalaipet V Ramanan; Stephanie de Bono; Cynthia E Kartman; Venkatesh Krishnan; Ran Liao; Maria Lucia B Piruzeli; Jason D Goldman; Jorge Alatorre-Alexander; Rita de Cassia Pellegrini; Vicente Estrada; Mousumi Som; Anabela Cardoso; Sujatro Chakladar; Brenda Crowe; Paulo Reis; Xin Zhang; David H Adams; E Wesley Ely
Journal:  Lancet Respir Med       Date:  2021-09-01       Impact factor: 102.642

3.  Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial.

Authors:  Olivier Sanchez; Anaïs Charles-Nelson; Walter Ageno; Stefano Barco; Harald Binder; Gilles Chatellier; Daniel Duerschmied; Klaus Empen; Melanie Ferreira; Philippe Girard; Menno V Huisman; David Jiménez; Sandrine Katsahian; Matija Kozak; Mareike Lankeit; Nicolas Meneveau; Piotr Pruszczyk; Antoniu Petris; Marc Righini; Stephan Rosenkranz; Sebastian Schellong; Branislav Stefanovic; Peter Verhamme; Kerstin de Wit; Eric Vicaut; Andreas Zirlik; Stavros V Konstantinides; Guy Meyer
Journal:  Thromb Haemost       Date:  2021-10-31       Impact factor: 6.681

Review 4.  Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

5.  Options and Considerations for Adaptive Laboratory Experiments.

Authors:  Lai Wei; David Jarjoura
Journal:  Stat Biosci       Date:  2014-11-25

6.  Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses.

Authors:  Ognjen Arandjelović
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

7.  Optimal promising zone designs.

Authors:  Samuel T Hsiao; Lingyun Liu; Cyrus R Mehta
Journal:  Biom J       Date:  2018-11-08       Impact factor: 2.207

8.  A systematic review of the "promising zone" design.

Authors:  Julia M Edwards; Stephen J Walters; Cornelia Kunz; Steven A Julious
Journal:  Trials       Date:  2020-12-04       Impact factor: 2.279

9.  Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.

Authors:  Per Broberg
Journal:  BMC Med Res Methodol       Date:  2013-07-19       Impact factor: 4.615
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.